-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.ISIN US45826J1051-
Intellia TherapeuticsBörse Börse FrankfurtSymbol 38I
-
Intellia TherapeuticsBörse Börse MünchenSymbol 38I
-
INTELLIA THERAPEUTICS INCBörse Börse StuttgartSymbol 38I
-
INTELLIA THERAPEUTICS INCBörse Gettex System der Börse MünchenSymbol 38I
-
INTELLIA THERAPEUTICS INCBörse Quotrix System der Börse DüsseldorfSymbol 38I
-
INTELLIA THERAPEUTICS INCBörse Tradegate System der Deutsche Börse AG (60%)Symbol 38I
-
INTELLIA THERAPEUTICS INCBörse Börse DüsseldorfSymbol 38I
-
ISIN US45826J1051 WKN: A2AG6HSymbol NTLA
-
Symbol 38I
-
Intellia Therapeutics, Inc.Börse London Stock Exchange
-
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
4.410.512.384 oder 8.662.000.000
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
270 oder 598 Mitarbeiter
Intellia Therapeutics outperformed den DAX um +160 % vom 06.05.2016 bis 18.06.2021
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 127,5 EUR +13,99%
Portrait der Intellia Therapeutics Aktie
Das Unternehmen Intellia Therapeutics, Inc aus USA beschäftigt 434 Mitarbeiter.
Die Intellia Therapeutics Aktie konnte seit dem 06.05.2016 eine Rendite von bemerkenswerten 219% erwirtschaften.
Das Unternehmen Intellia Therapeutics, Inc ist in ungefähr 10 ETFs enthalten und somit eine nicht sonderlich bekannte oder beliebte Aktie. Der Spitzenreiter Global X Genomics & Biotechnology ETF gewichtet Intellia Therapeutics mit 6,74% im ETF.
Entdecke die 6 ETFs in denen Intellia Therapeutics, Inc am höchsten gewichtet ist Insgesamt in 10 ETFs enthalten
Dir gefallen die Informationen zu Intellia Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Dir gefallen die Informationen zu Intellia Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Dir gefallen die Informationen zu Intellia Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Dir gefallen die Informationen zu Intellia Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
117 News & Informationen zur Intellia Therapeutics Aktie
Intellia Therapeutics, Inc. (NASDAQ:NTLA), has commenced an underwritten public offering of $400 million of shares of its common : stocks
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company using CRISPR/Cas9 technology both in vivo and ex vivo …
Crispr, the Tool Giving DNA Editing Promise and Peril
(Bloomberg) — Mankind has been manipulating genetics since early civilizations realized that certain traits of crops, animals and humans themselves were hereditary.
S&P, NASDAQ Keep Setting Records to Begin Big Week of Data
Stocks Analysis by Zacks Investment Research covering: Microsoft Corporation, Alcoa Corp, FedEx Corporation, Apple Inc. Read Zacks Investment Research's latest article on Investing.com
Intellia Shares Soar on Positive Test Results
GuruFocus Article or News written by Barry Cohen and the topic is about: Merck, Sanofi, Gilead and others stand to benefit from clinical trials
Stock Market Today: Chip Rip Triggers Record Highs in Nasdaq, S&P
Elsewhere, Facebook closed above the $1 trillion market-cap level for the first time ever.
ROUNDUP/Aktien New York Schluss: Rekordlauf geht weiter – Nur Dow Jones im Minus
ROUNDUP/Aktien New York Schluss: Rekordlauf geht weiter – Nur Dow Jones im Minus | Nachricht | finanzen.net
Aktien New York Schluss: Rekordlauf geht weiter – Nur Dow Jones im Minus
Mit Ausnahme des Dow Jones Industrial haben die wichtigsten US-Aktienindizes ihren Rekordlauf am Montag fortgesetzt. Gestützt haben dürfte unter anderem, dass Präsident Joe Biden am Wochenende von Veto-Plänen gegen die…
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.44% By Investing.com
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.44%
S&P 500, Nasdaq close at record highs as mega-cap tech spurs gains
The Charging Bull or Wall Street Bull is pictured in the Manhattan borough of New York City Reuters US stocks traded near record highs Monday …
Etsy, Intellia rise; Carnival, Exelixis fall
Stocks that traded heavily or had substantial price changes Monday: Etsy, Intellia rise; Carnival, Exelixis fall
Mid-Afternoon Market Update: Nasdaq Gains 100 Points; New Senior Investment Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.49% to 34,266.49 while the NASDAQ rose 0.72% to 14,463.26. The S&P also rose, gaining 0.05% to …
Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money
Find out why these stocks are climbing higher.
Mid-Day Market Update: Crude Oil Down Over 1%; Intellia Therapeutics Shares Jump
Midway through trading Monday, the Dow traded down 0.52% to 34,253.86 while the NASDAQ rose 0.72% to 14,463.56. The S&P also fell, dropping 0….
Why Beam Therapeutics Jumped Today
A first for CRISPR-Cas9 might signal a new phase in the gene-editing revolution.
Why Editas Medicine Stock Is Jumping Today
Good news for Intellia was viewed as good news for Editas.
Why Intellia Therapeutics Stock Is Skyrocketing Today
The company reported promising interim trial results for its CRISPR gene-editing candidate.
Aktien New York: Rekordlauf geht weiter – Nur Dow Jones gibt leicht nach
Nur mit Ausnahme des Dow Jones Industrial haben die wichtigsten US-Aktienindizes ihren Rekordlauf am Montag fortgesetzt. Stützend dürfte wirken, dass Präsident Joe Biden am Wochenende von Veto-Plänen gegen die…
Stocks That Hit 52-Week Highs On Monday
During the morning session on Monday, 118 stocks hit new 52-week highs.
Highlights: The company with the largest market cap to set a new …
Intellia Soars On Positive Results In Gene-Editing Treatment By Investing.com
Intellia Soars On Positive Results In Gene-Editing Treatment
Boeing, Tesla and Johnson & Johnson Fall Premarket By Investing.com
Boeing, Tesla and Johnson & Johnson Fall Premarket
Futures Stall At All Time High As Focus Turns To Jobs Data
ZeroHedge – On a long enough timeline, the survival rate for everyone drops to zero
Intellia Shares Climb on Positive Gene-Editing Data
By Matt Grossman
Intellia Therapeutics Inc. shares soared Monday morning after the company reported positive interim data from a Phase 1 clinical study of a gene-editing candidate… | June 28, 2021
Crispr, the Tool Giving DNA Editing Promise and Peril
Mankind has been manipulating genetics since early civilizations realized that certain traits of crops, animals and humans themselves were hereditary. The modern-day mapping of all human genes raised the prospects of learning precisely which genes control which traits and then directly altering their DNA codes. After years of hit-and-miss efforts, a gene-editing system called Crispr that’s cheap, effective and easy to use promises to change our relationship with genetics — for better, worse or b
24 Stocks Moving in Monday's Pre-Market Session
Gainers Intellia Therapeutics, Inc. (NASDAQ:NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceutica…
A Peek Into The Markets: US Stock Futures Mixed; Crude Oil Edges Lower
Pre-open movers U.S. stock futures traded mixed in early pre-market trade after the Dow Jones surged more than 230 points in the previous session…
The Washington Post
Mankind has been manipulating genetics since early civilizations realized that certain traits of crops, animals and humans themselves were hereditary. The modern-day mapping of all human genes raised the prospects of learning precisely which genes control which traits and then directly altering their DNA codes. After years of hit-and-miss efforts, a gene-editing system called Crispr that’s cheap, effective and easy to use promises to change our relationship with genetics — for better, worse or b
Pre-market Movers: NTLA, ABUS, ATOS, GTEC…
The following are some of the stocks making big moves in Monday's pre-market trading (as of 4.41 A.M.).
Intellia Announces Positive Interim Data On Transthyretin Amyloidosis Study
(RTTNews) – Intellia Therapeutics Inc. (NTLA) and Regeneron Pharmaceuticals Inc. (REGN) announced positive interim data from an ongoing phase 1 c…
4 Hot Stocks to Add to Your Growth Portfolio
With interest rates remaining at near-zero levels, supportive government policies have been driving the growth prospects of several companies. As such…
Intellia Therapeutics Names James Basta, J.D., As Executive Vice President, General Counsel And Corporate Secretary
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative
Blackstone Life Sciences, Cellex Cell Professionals, And Intellia Therapeutics Launch New CAR T-Cell Company
Blackstone BX announced today that funds managed by Blackstone Life Sciences have committed $250 million towards the launch of a new autologous and allogeneic
3 Biotech Stocks With Big Catalysts in June
Important events on the horizon could push these biotech stocks higher or press them further into the dirt.
Comprehensive report of Gene Editing Tools Market Projected to Gain Significant Value by 2029
The rising prevalence of cancer and other genetic disorders, such as sickle cell disease, heart disease, diabetes, Alzheimer’s disease, obesity, and others,
Microcap stock mania to start 2021 is a signal of more gains, and potential danger, ahead
The Russell Microcap index is having the best start to a year on record.
Stocks That Hit 52-Week Highs On Friday
This morning 150 companies reached new 52-week highs.
Interesting Points: Eli Lilly (NYSE:LLY) was the largest firm by market cap to set a new …
CRISPR, Editas, Intellia: Gene Editing Stocks To Play The Next Revolution In Medicine
Gene editing has emerged as a promising biotech theme. The technology is used to insert, edit, or delete a gene from an organism’s genome, helping to replace the defective genes responsible for a medical condition with healthy versions. This technology is being used to develop treatments for a…
Here’s Why Intellia Therapeutics (NTLA) is Trading Higher Lately
Intellia Therapeutics Inc. (NASDAQ:NTLA) is a biotech company working on a gene-editing technique called CRISPR/Cas9, which is a relatively new technology…
Portfolio Manager Thinks Gene-Editing Stocks Could Outperform Tesla
Portfolio Manager Thinks Gene-Editing Stocks Could Outperform Tesla, Stocks: TSLA,EDIT,CRSP,NTLA,ARKG,PACB,FATE,NVTA,IOVA,EXAS, release date:Jan 08, 2021
Stocks That Hit 52-Week Highs On Friday
This morning 470 companies set new 52-week highs.
Facts of Interest: Tesla (NASDAQ:TSLA) was the largest firm on a market cap basis to set a …
The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 7) …